The Technical Analyst
Metagenomi, Inc. Common [MGX]
Exchange: Nasdaq Sector: Healthcare Industry: Biotechnology
Metagenomi, Inc. Common Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.37% $6.47
America/New_York / 6 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 242.45 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 27, 2024 |
| SharesOutstanding: | 37.47 mill |
| Avg Daily Volume: | 0.226 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 5.63 - 7.31 ( +/- 13.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-08 | Novo Holdings A/s | Sell | 147 415 | SERIES B PREFERRED STOCK |
| 2024-02-08 | Novo Holdings A/s | Sell | 691 760 | SERIES B-1 PREFERRED STOCK |
| 2024-02-08 | Noonberg Sarah B. | Sell | 0 | Common Stock |
| 2024-02-08 | Borges Luis | Buy | 0 |
| INSIDER POWER |
|---|
| -100.00 |
| Last 3 transactions |
| Buy: 0 | Sell: 839 175 |
Forecast:
16:00 - $6.50
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.50
Forecast 2: 16:00 - $6.50
Forecast 3: 16:00 - $6.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.47 (2.37% ) |
| Volume | 0.0572 mill |
| Avg. Vol. | 0.226 mill |
| % of Avg. Vol | 25.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MGX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 12 - 10:26 | buy | $11.88 | N/A | Active |
|---|
MGX
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Latest Press Releases
2024-05-01 16:00:00 - Press Release
Metagenomi To Regain Full Development Rights To Its Wholly-owned Base Editing And Rigs Systems
Enhances strategic flexibility and control of key gene editing technologies and programs enhances strategic flexibility and control of key gene editing technologies and programs
2024-04-08 08:00:00 - Press Release
Metagenomi To Present At Upcoming Scientific Meetings
- oral presentation at world federation of hemophilia (wfh) world congress, april 23, 2024 - two posters at american society of gene & cell therapy (asgct) 2024 annual meeting, may 8 & 9, 2024 emeryville, calif., april 08, 2024 (globe newswire) -- metagenomi, inc. (nasdaq: mgx), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the company will present at two upcoming scientific meetings: a late breaking oral presentation at the world federation of hemophilia (wfh) world congress, taking place april 21 – 24, 2024 in madrid, spain and two poster presentations at the american society of gene & cell therapy (asgct) 2024 annual meeting, taking place may 7 – 11, 2024, in baltimore, md and virtually.
2024-03-27 09:16:00 - Press Release
Metagenomi Reports Business Updates And Full Year 2023 Financial Results
Demonstrated nonhuman primate proof of concept in hemophilia a program; progressing towards development candidate nomination by mid-year; 12-month nonhuman primate durability data in 2h 2024
2024-02-29 16:30:00 - Press Release
Metagenomi To Participate In The 44th Annual Cowen Healthcare Conference
Emeryville, calif., feb. 29, 2024 (globe newswire) -- metagenomi, inc. (nasdaq: mgx), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that brian c. thomas, ceo & founder, will participate in a panel titled, “emerging genetic therapy approaches,” during the 44th annual cowen healthcare conference on wednesday, march 6, 2024 from 12:50-1:50 pm et in boston.
2024-02-13 16:35:00 - Press Release
Metagenomi Announces Closing Of Initial Public Offering
Emeryville, calif., feb. 13, 2024 (globe newswire) -- metagenomi, inc. (nasdaq: mgx), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. the aggregate gross proceeds to metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. in addition, metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.
Latest News
2024-05-02 06:04:00 - InvestorPlace
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
2024-02-19 10:30:00 - The Motley Fool
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
Metagenomi just raised $94 million in its initial public offering. It now has enough money to last it for a few years.
2024-02-18 11:20:54 - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
2024-02-09 14:34:16 - Reuters
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
2024-02-08 23:07:44 - Reuters
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln
Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.